Generali Investments CEE investicni spolecnost a.s. Purchases 4,797 Shares of Biogen Inc. $BIIB

Generali Investments CEE investicni spolecnost a.s. lifted its position in Biogen Inc. (NASDAQ:BIIB) by 12.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,552 shares of the biotechnology company’s stock after buying an additional 4,797 shares during the quarter. Generali Investments CEE investicni spolecnost a.s.’s holdings in Biogen were worth $7,665,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Advisory Services Network LLC raised its holdings in Biogen by 3.9% in the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 68 shares during the period. CVA Family Office LLC grew its position in shares of Biogen by 18.1% in the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 71 shares during the last quarter. Davis Investment Partners LLC grew its position in shares of Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after purchasing an additional 71 shares during the last quarter. TD Private Client Wealth LLC increased its stake in shares of Biogen by 22.5% in the third quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 76 shares during the period. Finally, CX Institutional increased its stake in shares of Biogen by 6.1% in the third quarter. CX Institutional now owns 1,453 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 83 shares during the period. 87.93% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on BIIB. Piper Sandler increased their target price on Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research note on Monday, February 9th. Wolfe Research set a $231.00 price target on Biogen in a research report on Monday, February 9th. UBS Group initiated coverage on Biogen in a report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price target for the company. Royal Bank Of Canada increased their price objective on Biogen from $217.00 to $233.00 and gave the company an “outperform” rating in a research report on Monday, February 9th. Finally, Tudor Pickering set a $201.00 price objective on shares of Biogen in a research note on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Biogen has a consensus rating of “Hold” and a consensus target price of $205.31.

Biogen Stock Down 3.8%

BIIB stock opened at $183.84 on Friday. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The company has a market cap of $26.98 billion, a PE ratio of 20.87, a price-to-earnings-growth ratio of 1.52 and a beta of 0.15. The business’s 50-day simple moving average is $185.36 and its 200 day simple moving average is $170.05.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the prior year, the firm posted $3.44 EPS. The company’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.18% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.